Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01312389 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01312389 is a Phase 1 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 3 participants.
The verdict
NCT01312389, a Phase 1 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase I/II randomized study for subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-L, an autologous vaccine comprised of autologous Oxidized tumor Cell Lysate (OC-L) administered by intradermal/subcutaneous injection in combination with Ampligen (poly-l:poly-C12U), a Toll-like receptor 3 agonist. Study duration is 24 months.
Interventions
- BIOLOGICAL Prevnar
- BIOLOGICAL OC-L/Montanide ISA 51 VG
- BIOLOGICAL Ampligen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01312389
The ClinicalTrials.gov registry entry for NCT01312389 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prevnar is the first listed.
NCT01312389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01312389 about?
NCT01312389 is a clinical study titled "A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer". This is a Phase I/II randomized study for subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-L, an autologous vaccine comprised of autologous Oxidized tumor Cell Lysate (OC-L) administered by intraderma...
What is the current status of trial NCT01312389?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-04. Estimated completion is 2012-08-17.
What interventions are being tested in trial NCT01312389?
The interventions under investigation include: Prevnar (BIOLOGICAL), OC-L/Montanide ISA 51 VG (BIOLOGICAL), Ampligen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01312389?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.